Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Category Scores
Accurate Statements
The size of cholesterol reduction generally varies with the dose of atorvastatin.
Supported indirectly by label language that starting/maintenance doses should be individualized according to patient characteristics and response, and that lipid levels are analyzed after initiation/titration with dose adjustment (Section 2.1).
The size of cholesterol reduction generally varies with the patient’s starting lipid levels.
Supported indirectly by label language that dosing should be individualized according to patient characteristics such as goal of therapy and response (Section 2.1), and that therapeutic response is monitored and adjusted (Section 2.1).
Unsupported Statements
Lipitor lowers LDL (“bad”) cholesterol by a mean reduction of about 37% from baseline in clinical studies.
The provided label excerpts do not contain this specific quantitative mean percent (37%) LDL reduction.
Lipitor lowers total cholesterol by about a 27% mean decrease.
The provided label excerpts do not contain this specific quantitative mean percent (27%) total cholesterol decrease.
Lipitor lowers triglycerides by about a 19% mean decrease.
The provided label excerpts do not contain this specific quantitative mean percent (19%) triglyceride decrease.
Lipitor increases HDL (“good”) cholesterol by about a 5% mean increase.
The provided label excerpts do not contain this specific quantitative mean percent (5%) HDL increase.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Moderate
Quantitative efficacy claims may mislead expectations; however, no direct contraindication or safety claim was made. The main issue is the lack of support for the specific mean percentage figures in the supplied label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Specific mean percentage lipid changes (LDL 37%, total-C 27%, TG 19%, HDL 5%) are not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or revise the specific numeric mean percent reductions/increases unless supported by the exact label table/section. Keep only qualitative statements that response and dose effects are individualized/adjusted based on lipid monitoring (Section 2.1) and that Lipitor reduces total-C/LDL-C/TG and increases HDL-C (Section 14.2).